MDxHealth (NASDAQ:MDXH) Shares Down 2.2% - Here's What Happened

Key Points

• MDxHealth's stock price fell by 2.2% to close at $4.05, with trading volume decreasing significantly to about 40,793 shares, down 74% from average levels.
• Equities analysts have mixed ratings on MDxHealth, with a consensus of "Moderate Buy" and a price target of $7.00, while one analyst issued a "sell" recommendation.
• The company reported a quarterly EPS of ($0.15), missing estimates, and had a negative net margin of 34.98%, indicating financial challenges amidst changing institutional investments.

MDxHealth SA (NASDAQ:MDXH - Get Free Report)'s stock price was down 2.2% on Tuesday . The company traded as low as $4.00 and last traded at $4.05. Approximately 40,793 shares traded hands during mid-day trading, a decline of 74% from the average daily volume of 156,851 shares. The stock had previously closed at $4.14.

Wall Street Analysts Forecast Growth

A number of equities analysts recently weighed in on MDXH shares. Craig Hallum started coverage on MDxHealth in a research report on Thursday, July 17th. They issued a "buy" rating and a $8.00 price target for the company. Weiss Ratings reiterated a "sell (e+)" rating on shares of MDxHealth in a research report on Wednesday, October 8th. Finally, Wall Street Zen upgraded MDxHealth to a "hold" rating in a research report on Saturday, August 30th. Three analysts have rated the stock with a Buy rating and one has given a Sell rating to the company's stock. Based on data from MarketBeat, MDxHealth has an average rating of "Moderate Buy" and a consensus price target of $7.00.

MDxHealth Trading Down 2.2%

The firm has a market capitalization of $191.52 million, a price-to-earnings ratio of -4.60 and a beta of 1.65. The company has a current ratio of 1.31, a quick ratio of 1.22 and a debt-to-equity ratio of 13.81. The company has a fifty day moving average price of $3.88 and a 200-day moving average price of $2.69.

MDxHealth (NASDAQ:MDXH - Get Free Report) last announced its quarterly earnings results on Tuesday, August 5th. The company reported ($0.15) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.13) by ($0.02). The firm had revenue of $26.60 million for the quarter, compared to analyst estimates of $26.60 million. MDxHealth had a negative net margin of 34.98% and a negative return on equity of 374.98%. MDxHealth has set its Q2 2025 guidance at -0.150--0.150 EPS. On average, equities research analysts predict that MDxHealth SA will post -1.15 EPS for the current year.

Institutional Inflows and Outflows

A number of institutional investors have recently made changes to their positions in the stock. Calamos Advisors LLC bought a new position in shares of MDxHealth in the 3rd quarter valued at approximately $305,000. FreeGulliver LLC bought a new position in shares of MDxHealth in the 2nd quarter valued at approximately $273,000. Delta Investment Management LLC raised its stake in shares of MDxHealth by 459.1% in the 1st quarter. Delta Investment Management LLC now owns 190,100 shares of the company's stock valued at $270,000 after acquiring an additional 156,100 shares in the last quarter. Perkins Capital Management Inc. raised its stake in shares of MDxHealth by 20.1% in the 1st quarter. Perkins Capital Management Inc. now owns 1,181,475 shares of the company's stock valued at $1,678,000 after acquiring an additional 198,000 shares in the last quarter. Finally, AWM Investment Company Inc. raised its stake in shares of MDxHealth by 10.6% in the 1st quarter. AWM Investment Company Inc. now owns 5,221,282 shares of the company's stock valued at $7,414,000 after acquiring an additional 499,992 shares in the last quarter.

MDxHealth Company Profile

MDxHealth SA, a commercial-stage precision diagnostics company, provides urologic solutions in the United States, Europe, and internationally. Its testing solutions includes Select mdx, a non-invasive urine test for prostate cancer that measures the expression of two mRNA cancer-related biomarkers; Confirm mdx for prostate cancer tissue test that validates epigenetic test that guides the detection of occult prostate cancer on a patient's previously biopsied negative tissue; and Resolved mdx for urinary tract infection that identifies personalized effective antibiotic options against the patient's infection.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.